Vanflyta (Quizartinib Dihydrochloride) Patent Expiration, LOE Window & CMS Spending
Vanflyta (Quizartinib Dihydrochloride) by Daiichi Sankyo: FDA Orange Book core substance LOE 2028-09-26 (last listed 2033-09-30), 0 AB generics, $10.7M 2024 CMS Part D & Medicaid spend, and $15,288 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Daiichi Sankyo |
| FDA Application & Pathway | N216993 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2028-09-26 |
| Last Listed Patent or Exclusivity Date | 2033-09-30 |
| Orange Book Patents (*PED Extensions) | 11 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $10.7M |
| 2024 Medicare Part D Spend | $7.9M |
| 2024 Medicaid Spend | $2.9M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($15,288 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Daiichi Sankyo across sibling Meru public-data platforms.